This report draws attention to a moment of opportunity for implementing scaled pre-exposure prophylaxis (PrEP) with the introduction of the six-month injectable Lenacapavir. Highlighting progress made so far as well as persistent gaps that require a multisectoral coordinated approach involving governments, donors, civil society and networks among others to ensure equitable access of the innovative tool to all populations at risk including those in unprecedented geographic regions.